However, in the present study, the extent of serum HBsAg level reduction during the TAF treatment period did not associate with serum levels of GGT and cholesterol as well as AST/ALT ratio at the during switching, suggesting that serum HBsAg level reduction did not associate with the extent of hepatic steatosis. The gene discussed is GPT; the disease is fatty liver disease.